Valeant Shares Jump 6% on Solid Forecast, “New Strategic Direction”

Share This Article
August 9, 2016 9:10am NYSE:VRX

Image of multi colored pillsEmbattled pharma giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Tuesday posted weaker-than-expected second quarter results, but stood by its yearly forecast and announced a vague plan to return the company to normalcy.

The Quebec, Canada-based company reported a second quarter net loss of 302.3 million, or -88 cents per share. Analysts had expected a profit of $1.61 per share.

Revenue fell 11.4% from last year to $2.42 billion, also missing estimates of $2.59 billion.

Despite the very weak quarter, VRX left its forecast in tact. Looking ahead, the company reiterated its prior full-year outlook for EPS of $6.60 to $7.00 on revenue of $9.9 billion to $10.1 billion.

From the press release:

“We continue to make progress towards stabilizing the organization,” said Joseph C. Papa, chairman and chief executive officer. “We are also announcing a new strategic direction for Valeant today, which, at its heart has a mission to improve patients’ lives, and will involve reorganizing our company and reporting segments. I am continuously encouraged by the commitment of our employees who work hard daily, rebuilding our relationships with prescribers, patients and payors, and regaining the trust of our debt holders and shareholders. Although it will take time to implement and execute our turnaround plan, I am confident that we will show progress in the coming quarters.”

The company didn’t offer and details around its turnaround plan, but investors certainly cheered the announcement.

Valeant shares, which have plunged 78% since the start of 2016 amid a drug pricing scandal, rose $1.40 (+6.24%) to $23.85 in premarket trading Tuesday.


Read Next

Get Free Updates

Join over 50,000 investors who get the latest news from!

Most Popular

From Our Partners

Explore More from

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again! respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories